[Prognosis for branch retinal vein occlusion].
OBJECTIVE
To evaluate the visual outcomes of various kinds of treatment for branch retinal vein occlusion (BRVO).


METHODS
The medical records of 222 BRVO eyes without any previous treatment were reviewed. One-year visual acuity (VA) and 1-year visual gains (VG) were analyzed for each treatment.


RESULTS
The one-year VA correlated with the initial VA and 1-year VG negatively correlated with the initial VA. The initial and 1-year VA of the observation group (17.6%) were 0.6 and 0.8, respectively. No difference in the 1-year VA was found among the various treatments and the average 1-year VG was 1.1 lines. The one-year VA of the single treatment group (36.0%) was 0.62 on average, without any difference between the various treatments, while only the PPV group had better 1-year VG (4.4 lines). The multiple treatment group (46.4%)showed worse initial VA (0.33), 1-year VA (0.39) and 1-year VG (0.7 line).


CONCLUSIONS
Patients with better initial VA can be observed without any treatment. As a whole, the 1-year VG is about one line and some significant visual improvement can be expected regardless of the treatments. The PPV group showed larger visual gain for eyes with worse initial visual acuity. Approximately half of the patients could not achieve any improvement by a single treatment and had a poor visual prognosis.
Department of Ophthalmology, Osaka University Graduate School of Medicine. syano@kinan-hp.tanabe.wakayama.jp
Shinsaku
S
Yano
Motohiro
M
Kamei
Mihoko
M
Suzuki
Kohji
K
Nishida
D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008028:Light Coagulation; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012170:Retinal Vein Occlusion / Q000503:physiopathology / Q000628:therapy*; D012189:Retrospective Studies; D014222:Triamcinolone Acetonide / Q000627:therapeutic use; D014792:Visual Acuity; D014821:Vitrectomy
D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide